Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Novara – page 81

2 684 clinical trials in Novara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Novara at a glance
2 684
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 684 trials in Novara

Open in trial search

Non-small cell lung cancer

Recruiting

Study on the Safety and Effectiveness of Zipalertinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Specific EGFR Mutations

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Digoxin
  • Sponsor:Taiho Oncology Inc.

Systemic lupus erythematosus

Recruiting

Study of Anifrolumab for Children and Teens with Moderate to Severe Lupus

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Plasma cell myeloma

Recruiting

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Prophylaxis of nausea and vomiting

Recruiting

Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on the Safety and Tolerability of ODM-212 for Patients with Advanced Solid Tumors

Recruiting
InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Orion Corporation

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Breast cancer metastatic+1

Recruiting

Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Hodgkin's disease

Recruiting

Study on the Effectiveness and Safety of Tislelizumab for Patients with Newly Diagnosed Hodgkin Lymphoma Who Cannot Have Standard Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Tislelizumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Haematological malignancy

Recruiting

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:KITE-363
  • Sponsor:Kite Pharma Inc.

Juvenile idiopathic arthritis

Recruiting

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Tocilizumab
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Novara

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on hematologic malignancies and solid tumors, investigating innovative treatments for various cancer types including leukemia, breast cancer, and lung cancer.

  • Advanced breast cancer therapies
  • Chronic myeloid leukemia treatments
  • Non-small cell lung cancer interventions

Studies evaluating combination therapies and targeted treatments to improve patient outcomes.

02 Cardiovascular Studies

Research focusing on heart failure prevention and treatment strategies, particularly exploring new drug combinations and their impact on cardiovascular outcomes.

  • Heart failure risk reduction
  • Cardiovascular death prevention
  • Chronic kidney disease management

Innovative approaches combining multiple therapeutic agents to address cardiovascular risks.

03 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Sjögren's Syndrome and rheumatoid arthritis, with emphasis on novel therapeutic approaches.

  • Biomarker-guided treatments
  • Long-term safety evaluations
  • Innovative therapeutic combinations

Focus on developing targeted therapies for better disease management and patient care.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.